Fineline Cube

Follow:
14778 Articles
Gilead Sciences to Withdraw Accelerated Approval of Trodelvy in Urothelial Carcinoma
CompanyDrug

Gilead Sciences to Withdraw Accelerated Approval of Trodelvy in Urothelial Carcinoma

Jiangsu Hengrui Medicine Initiates Phase III Clinical Trial for SHR-A1904 in Gastric Cancer
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Initiates Phase III Clinical Trial for SHR-A1904 in Gastric Cancer

MicroPort Sorim CRM's PLATINIUM Series ICD Receives NMPA Approval, A First for China
CompanyMedical Device

MicroPort Sorim CRM’s PLATINIUM Series ICD Receives NMPA Approval, A First for China

Jacobio Pharma's G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer
CompanyDrug

Jacobio Pharma’s G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer

MicroPort NeuroTech's NUMEN Silk Receives FDA Approval for Embolization Treatment
CompanyDrug

MicroPort NeuroTech’s NUMEN Silk Receives FDA Approval for Embolization Treatment

Astellas Pharma's Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment
CompanyDrug

Astellas Pharma’s Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment

Westgene Biopharma's Pioneering mRNA Vaccine for EBV-Related Tumors Clears IND Hurdle in China
CompanyDrug

Westgene Biopharma’s Pioneering mRNA Vaccine for EBV-Related Tumors Clears IND Hurdle in China

Kanghong Pharmaceutical's NASH Drug KH629 Receives Clinical Trial Implicit Approval in China
CompanyDrug

Kanghong Pharmaceutical’s NASH Drug KH629 Receives Clinical Trial Implicit Approval in China

Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation
Company

Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation

Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer
CompanyDrug

Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer

FDA Extends Review of Amgen's Lumakras for KRAS G12C mCRC Treatment to January 2025
CompanyDrug

FDA Extends Review of Amgen’s Lumakras for KRAS G12C mCRC Treatment to January 2025

Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA
CompanyDrug

Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA